natgillin/translations-raw huggingface dataset:
The MULTAQ Information Card should contain a list of medicinal products which interact with MULTAQ classified according to the seriousness of the interaction (e.g. contraindication, not recommended, use with caution).
Informativna kartica o zdravilu MULTAQ mora obsegati seznam zdravil, ki medsebojno delujejo z zdravilom MULTAQ, razvrščenih glede na resnost medsebojnega delovanja (npr. kontraindicirana, nepriporočljiva, uporabljajte previdno).
The Multinational Association of Supportive Care in Cancer (MASCC) guidelines recommend the administration of dexamethasone with 5HT3 antagonist prior to chemotherapy.
Smernice Mednarodne zveze za podporno zdravljenje raka (Multinational Association of Supportive Care in Cancer; MASCC) priporočajo uporabo deksametazona z antagonistom 5HT3 pred kemoterapijo.
The multiple event analysis revealed a significant risk reduction of 16 % in patients treated with zoledronic acid 4 mg in comparison with patients receiving pamidronate.
Analiza večkratnih dogodkov je pokazala pomembno zmanjšanje tveganja za 16 % pri bolnikih, zdravljenih z zoledronsko kislino 4 mg, v primerjavi z bolniki, ki so prejemali pamidronat.
The multiple event analysis revealed a significant risk reduction of 16% in patients treated with 4 mg zoledronic acid in comparison with patients receiving pamidronate.
Analiza multiplih dogodkov je pokazala značilno, 16% zmanjšanje tveganja pri prejemnikih zoledronske kisline v primerjavi s prejemniki pamidronata.
The multiple event analysis revealed a significant risk reduction of 16% in patients treated with zoledronic acid 4 mg in comparison with patients receiving pamidronate.
Analiza večkratnih dogodkov je pokazala pomembno zmanjšanje tveganja za 16% pri bolnikih, zdravljenih z zoledronsko kislino 4 mg, v primerjavi z bolniki, ki so prejemali pamidronat.
The mutation causes problems with protein channels involved in the production of secretions such as mucus and digestive juices.
Ta mutacija povzroči težave z beljakovinskimi kanalčki, ki sodelujejo pri tvorbi izločkov, kot so sluzi in prebavni sokovi.
The mutational profiles were similar to those described for PI- experienced adults treated with fosamprenavir / ritonavir.
Profili mutacij so bili podobni tistim pri odraslih bolnikih, ki so se predhodno že zdravili z zaviralci proteaz in so se zdravili s fosamprenavirjem/ritonavirjem.
The mutations not amenable to treatment with Galafold are listed in Table 3 below:
Mutacije, ki na zdravljenje z zdravilom Galafold niso odzivne, so navedene v preglednici 3.
The MYCLIC pre-filled pen
Napolnjeni peresnik MYCLIC
The myITT population comprised 123 patients receiving isavuconazole and 108 patients receiving voriconazole.
Populacija myITT je obsegala 123 bolnikov, ki so prejemali izavukonazol, in 108 bolnikov, ki so prejemali vorikonazol.
The N- desmethylated derivative of ivabradine has been identified as the main active metabolite in humans.
N-demetilirani derivat ivabradina so določili kot poglavitni aktivni presnovek pri ljudeh.
The N-desmethyl metabolite is further metabolised, with a terminal half-life of approximately 4 h.
N-dezmetilni presnovek se presnovi naprej; razpolovni čas terminalne faze je približno 4 ure.
The N-methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose.
Na računa N-metiliranega derivata pregabalina, ki je glavni presnovek pregabalina v urinu, je šlo 0,9% odmerka.
The N-monodesmethyl metabolite (M2) is not thought to contribute significantly to clinical efficacy given its lower average exposure (23% to 31%) in humans and lower antimycobacterial activity (3- to 6-fold lower) compared to the parent compound.
N-monodesmetilni presnovek (M2) domnevno ne prispeva bistveno h klinični učinkovitosti, saj je povprečna izpostavljenost M2 pri človeku manjša od izpostavljenosti matični spojini (23% do 31%), njegova protibakterijska aktivnost pa je 3 do 6-krat manjša od aktivnosti izhodne učinkovine.
The name of my Doctor is:
Ime mojega zdravnika je:
The name of the medicine was changed to Cancidas on 9 April 2003.
Ime zdravila je bilo 9. aprila 2003 spremenjeno v Cancidas.
The name of the medicine was changed to Clopidogrel Teva Pharma on 20 October 2009.
Ime zdravila je bilo 20. oktobra 2009 spremenjeno v Clopidogrel Teva Pharma.
The name of the medicine was changed to Ifirmasta on 24 September 2009.
Ime zdravila je bilo 24. septembra 2009 spremenjeno v Ifirmasta.
The name of the medicine was changed to Imnovid on 27 August 2013.
Ime zdravila je bilo 27. avgusta 2013 spremenjeno v Imnovid.
The name of the medicine was changed to Sevohale on 29 July 2016.
Ime zdravila je bilo spremenjeno v Sevohale 29. julija 2016.
The name of the medicine was changed to Taxespira on 12 October 2015.
Honey Lane, Hurley, Maidenhead, SL6 6RJ,
The name of the medicine was changed to Thalidomide Celgene on 22 October 2008.
Ime zdravila je bilo 22. oktobra 2008 spremenjeno v Thalidomide Celgene.
The name of the medicine was changed to Toujeo on 24 April 2015.
Ime zdravila je bilo 24. aprila 2015 spremenjeno v Toujeo.
The name of the medicine was changed to Trevicta on
Ime zdravila je bilo
The name of this medicine is Docetaxel Winthrop.
To zdravilo se imenuje Docetaxel Winthrop.
The name of your medicine is Inhixa.
Vaše zdravilo se imenuje Inhixa.
The name of your medicine is Thorinane.
Vaše zdravilo se imenuje Thorinane.
The name of your medicine is Tredaptive.
Vaše zdravilo se imenuje Tredaptive.
The name Repatha appears on the pre-filled syringe label.
da je na nalepki napolnjene injekcijske brizge navedeno ime zdravila Repatha.
The nasal spray comes in a brown glass bottle inside a plastic casing - see picture a.
Nosno pršilo je na voljo v rjavi stekleni steklenički v plastičnem ohišju – glejte sliko a.
The nasal spray comes in an amber glass bottle inside a plastic casing - see picture a.
Pršilo za nos je na voljo v steklenički jantarne barve v plastičnem ohišju – glejte sliko a.
The nasal spray comes in four different pack sizes: 2.0 ml (equal to 10 doses), 3.2 ml (equal to 20 doses), 4.3 ml (equal to 30 doses) and 5.3 ml (equal to 40 doses).
Pršilo za nos je na voljo v štirih različnih velikostih pakiranja: 2,0 ml (ustreza 10 odmerkom), 3,2 ml (ustreza 20 odmerkom), 4,3 ml (ustreza 30 odmerkom) in 5,3 ml (ustreza 40 odmerkom).
The nasal spray is empty when the display shows ‘0’ and the lock symbol appears.
Pršilo za nos je prazno, ko se na zaslonu prikažeta vrednost »0« in simbol ključavnice.
The nasal spray is ready, when the display shows the number of doses (i.e.
Pršilo za nos je pripravljeno, ko se na zaslonu prikaže število odmerkov (tj.
The nasal spray is supplied in a child-resistant outer box and comes in three different pack sizes:
Pršilo za nos je shranjeno v za otroke varni škatli in ima tri različne velikosti pakiranja:
The natural history of untreated infant hypophosphatasia patients suggests high mortality if ventilation is required.
Naravni potek bolezni pri nezdravljenih bolnikih z infantilno hipofosfatazijo kaže, da je smrtnost velika, če je potrebna ventilacija.
The nature and incidence of adverse events were similar between treatment groups.
Značaj in incidenca neželenih učinkov sta bila podobna v vseh skupinah.
The nature and incidence of adverse reactions were similar between treatment groups.
Značaj in incidenca neželenih učinkov sta bila pri skupinah podobna.
The nature of your genotype (a genetic make up of all active genes in human cells, which determines one’s specific, individual characteristics) may influence your therapeutic response to this medicine, as well as your risk of developing antibodies and infusion-related side effects.
Narava vašega genotipa (genske sestave vseh aktivnih genov v človeških celicah, ki določa posameznikove posebne, individualne značilnosti) lahko vpliva na terapevtski odziv na to zdravilo ter na tveganje za razvoj protiteles in pojav neželenih učinkov, povezanih z infuzijo.
The nebuliser handset must be kept horizontally during operation.
Nebulator mora biti med uporabo vodoravno.
The nebuliser turns Ventavis solution into a mist which you breathe in through your mouth.
Nebulator spremeni raztopino zdravila Ventavis v meglico, ki jo vdihnete skozi usta.
The necessity to carry the patient alert card, that is included in each pack, with them at all times
Nujnost, da ima bolnik vedno pri sebi kartico z opozorili za bolnika, priloženo vsakemu pakiranju
the need and duration of barrier contraception
o potrebe po pregradni kontracepciji in glede trajanja njene uporabe;
The need for a booster dose of HBVAXPRO is not yet defined beyond the 12 month booster dose required for the 0, 1, 2 compressed schedule.
Potreba po obnovitvenem odmerku cepiva HBVAXPRO še ni določena, razen 12 mesečnega obnovitvenega odmerka, ki je potreben po skrčeni shemi 0, 1, 2.
The need for a full ophthalmological assessment 3-4 months after starting GILENYA therapy for the early detection of visual impairment due to drug-induced macular oedema.
3-4 mesece po začetku zdravljenja z zdravilom GILENYA je treba opraviti celoten oftalmološki pregled za zgodnje odkrivanje okvare vida zaradi makularnega edema, ki ga povzročajo zdravila.
The need for a guidance table highlighting pre-treatment measurements of serum creatinine, creatinine clearance, proteinuria, hepatic enzymes, ferritin, such as:
potrebnost vodenja in upoštevanja preglednice, ki opozarja na naslednje meritve pred zdravljenjem: koncentracije kreatinina v serumu, očistka kreatinina, proteinurije in vrednosti jetrnih encimov ter feritina, kot je prikazano:
The need for a liver function test prior to treatment initiation and for liver function monitoring at months 1, 3, 6, 9 and 12 during GILENYA therapy and periodically thereafter.
Pomembnost določanja jetrnih testov pred začetkom zdravljenja, po 1, 3, 6, 9 in 12 mesecih zdravljenja z zdravilom GILENYA in občasno tudi kasneje.
The need for a periodic monitoring with electrocardiograms and electrolytes should be considered when using XALKORI in these patients.
Kadar se zdravilo XALKORI uporablja pri teh bolnikih, je treba razmisliti o rednem spremljanju z elektrokardiogrami in preverjanjem elektrolitov.
The need for adequate contraception and definition of adequate contraception
Potrebo po ustrezni kontracepciji in definicijo ustrezne kontracepcije
The need for adequate contraceptive measures during treatment and for 24 months after Erivedge treatment
potreba po ustrezni kontracepcijski zaščiti med zdravljenjem in 24 mesecev po končanem zdravljenju
The need for an ECG, and serum levels of potassium, calcium and magnesium and thyroid stimulating hormone (TSH) and the times and situations when it should be performed
Trenutki in okoliščine kadar je treba izvesti preiskavo EKG, določitev serumskih ravni kalija, kalcija in magnezija ter tiroideo-stimulirajočega hormona.
The need for an increased dose relative to that used for adults and older children should be anticipated when treating younger children (less than 6 years of age) with ReFacto AF.
Pri zdravljenju mlajših otrok (mlajši od 6 let) z zdravilom ReFacto AF moramo pričakovati potrebo po zvečanem odmerku v primerjavi s tistim, ki se uporablja pri odraslih in starejših otrocih.
The need for annual auditory and ophthalmic testing
potrebnost enkrat letnega slušnega in okulističnega pregleda;
The need for anti- epileptic treatment should be reviewed in patients planning to become pregnant.
Potrebo po antiepileptičnem zdravljenju pri bolnicah, ki želijo zanositi, je treba ponovno preučiti.
The need for anti-epileptic therapy should be reviewed when a woman is planning to become pregnant.
Pri ženskah, ki načrtujejo nosečnost, je treba potrebo po zdravljenju epilepsije znova oceniti.
The need for anti-epileptic treatment should be reviewed in patients planning to become pregnant.
Potrebo po antiepileptičnem zdravljenju pri bolnicah, ki želijo zanositi, je treba ponovno preučiti.
The need for baseline and:
Potrebo po izhodiščnem in:
The need for comprehensive ophthalmological examinations including visual acuity, slit-lamp examination, dilated fundus photography and macular optical coherence tomography (OCT) imaging at treatment initiation and at least every 6 months thereafter while treatment is ongoing.
V času zdravljenja je treba na začetku zdravljenja in vsaj vsakih 6 mesecev opraviti izčrpen oftalmološki pregled, vključno z ostrino vida, pregledom s špranjsko svetilko, slikanjem očesnega ozadja ob dilataciji in optično koherentno tomografijo (OCT) makule.
The need for consistent and standard inhalation technique to ensure both optimal and consistent product delivery
potrebi po doslednem in standardnem načinu inhaliranja, ki naj zagotovi optimalen in konsistenten vnos zdravila,
The need for continued observation for patients with risk factors for toxin spread from the site of injection to other parts of the body and identification of these patients so caution can be exercised.
Potreba po stalnem opazovanju bolnikov z dejavniki tveganja za širjenje toksina z mesta injiciranja v druge dele telesa in prepoznavanje teh bolnikov, kar bo omogočilo izvajanje previdnostnih ukrepov.
The need for continued therapy should be considered at least on an annual basis as determined by physician assessment of the patient’s disease severity and level of control of exacerbations.
Potrebo po nadaljevanju zdravljenja je potrebno pretehtati vsaj enkrat na leto glede na zdravnikovo oceno izrazitosti bolnikove bolezni in doseženega nadzora nad poslabšanji.
The need for continued treatment should be evaluated after 16 weeks (see section 4.1) and re- evaluated annually.
Po 16 tednih je treba oceniti, ali je potrebno nadaljnje zdravljenje (glejte poglavje 4.1), nato pa je treba vsako leto to ponovno oceniti.
The need for early recognition of symptoms that could indicate spread of toxin e.g. swallowing, speech or respiratory difficulties.
Potreba po zgodnjem prepoznavanju simptomov, ki bi lahko nakazovali na širjenje toksina, npr. težave pri požiranju, govoru ali dihanju.
The need for effective contraception
potrebna je učinkovita kontracepcija
The need for effective contraception in women of childbearing potential during and up to five months after treatment.
Med zdravljenjem in do pet mesecev po njem morajo ženske v rodni dobi uporabljati učinkovito kontracepcijo.
The need for effective contraception, without interruption, 4 weeks before starting treatment, throughout the entire duration of treatment, and 4 weeks after the end of treatment
potrebna je zanesljiva kontracepcija brez prekinitev, 4 tedne pred pričetkom zdravljenja, med celotnim trajanjem zdravljenja ter 4 tedne po koncu zdravljenja
the need for genetic testing to be performed prior to the initiation of treatment in order to identify the patients who are eligible for treatment
potrebo po genskih preiskavah, ki jih je treba opraviti pred začetkom zdravljenja, da se ugotovijo bolniki, primerni za zdravljenje;
The need for intake of the 15 mg and 20 mg tablets with food
o pomembnosti jemanja tablet po 15 mg in 20 mg skupaj s hrano
The need for intake of the 15 mg and 20 mg tablets with food
pomembnost jemanja tablet po 15 mg in 20 mg skupaj s hrano
The need for liver function monitoring at months 1, 3, 6, 9 and 12 during GILENYA therapy and periodically thereafter.
Jetrne teste je treba določati po 1, 3, 6, 9 in 12 mesecih zdravljenja z zdravilom GILENYA in občasno tudi kasneje.
The need for liver function tests prior to prescription, then at monthly intervals or more often if clinically indicated
potrebnost izvajanja testov jetrne funkcije preden se predpiše zdravilo, nato pa v mesečnih intervalih ali bolj pogosto, če je klinično indicirano,
The need for monitoring of white blood cell cysteine levels, full blood count and liver function.
potrebo po spremljanju koncentracij cisteina v belih krvnih celicah, krvne slike in delovanja jeter;
The need for monthly pregnancy tests
potreba po mesečnem opravljanju testov nosečnosti
The need for ophthalmological assessment during treatment with GILENYA in patients with diabetes mellitus or with a history of uveitis.
Pri bolnikih s sladkorno boleznijo ali z anamnezo uveitisa je treba med zdravljenjem z zdravilom GILENYA opraviti oftalmološki pregled.
The need for pain management
Potreba po protibolečinskemu zdravljenju
The need for prescribing and dispensing with attention to pharmaceutical form (prolonged release) and posology (once daily administration).
Pri predpisovanju in izdajanju zdravila je potrebna pozornost zaradi farmacevtske oblike (podaljšano sproščanje) in odmerjanja (odmerjanje enkrat na dan).
The need for regional or spinal anaesthesia
Potreba po regionalni ali spinalni anesteziji
The need for rehabilitation following articular cartilage repair
Potreba po rehabilitaciji po popravilu sklepnega hrustanca.
The need for specialist supervision and monitoring if there is a clinical decision to switch a patient to another tacrolimus containing products.
Pri klinični odločitvi o prehodu bolnika na drugo zdravilo, ki vsebuje takrolimus, mora zdravljenje nadzirati in spremljati specialist.
The need for subsequent implantations should be based on the increase of testis size and/or increase in plasma testosterone concentrations as well as return to sexual activity.
Potreba po naslednji implantaciji mora temeljiti na povečanju velikosti testisov in/ali povečanju plazemske koncentracije testosterona ter vrnitvi spolne aktivnosti.
The need for treatment continuation should be reconsidered every 6 months.
Potrebo po nadaljnjem zdravljenju je treba pretehtati vsakih 6 mesecev.
The need for, or timing of, a booster dose with ZOSTAVAX has not yet been determined.
Potreba po obnovitvenem odmerku cepiva ZOSTAVAX ali čas njegove uporabe še nista bila določena.
The need to advise patients about:
potrebo po tem, da se bolnike seznani:
The need to advise patients on:
Potreba po svetovanju bolnikom glede:
The need to advise women (even if a woman has amenorrhoea) on the use of reliable contraception during treatment and for one month following permanent discontinuation of treatment.
Ženskam (tudi ženskam z amenorejo) je treba svetovati, da morajo med zdravljenjem in še en mesec po trajni ukinitvi zdravljenja uporabljati zanesljivo kontracepcijo.
The need to advise women of child-bearing potential on the serious risk to the foetus and the need to practice effective contraception during treatment and for at least two months following discontinuation of treatment with GILENYA.
Ženske v rodni dobi je treba opozoriti glede resnega tveganja za plod in glede uporabe učinkovite kontracepcijske metode v času zdravljenja in še najmanj dva meseca po prekinitvi zdravljenja z zdravilom GILENYA.
The need to assess the risk of TB in patients prior to treating with Flixabi.
Potrebo po oceni tveganja za TB pri bolnikih pred začetkom zdravljenja z zdravilom Flixabi.
The need to avoid alcohol;
Potrebo po izogibanju alkoholu;
The need to avoid foetal exposure
opozorilo, da je treba preprečiti izpostavljenost ploda
The need to avoid foetal exposure
treba je preprečiti izpostavljenost ploda
The need to avoid foetal exposure due to teratogenicity of pomalidomide in animals and the expected teratogenic effect of pomalidomide in humans
potrebo po izogibanju fetalni izpostavljenosti zaradi teratogenosti pomalidomida pri živalih in pričakovanega teratogenega učinka pomalidomida na človeka;
The need to avoid grapefruit juice;
Potrebo po izogibanju soku grenivke;
The need to call the doctor in case of treatment interruption as the 1st dose monitoring may need to be repeated depending on duration of the interruption and time since start of GILENYA treatment.
Pomembnost obveščanja zdravnika v primeru prekinitve zdravljenja, saj je morda treba ponoviti spremljanje bolnika kot pri prvem odmerjanju, kar je odvisno od trajanja prekinitve in časa od začetka zdravljenja z zdravilom GILENYA.
The need to carefully consider use of necitumumab in patients with a history of thromboembolic events or pre-existing risk factors for thromboembolic events
Potreba po natančnem razmisleku o uporabi necitumumaba pri bolnikih s trombemboličnimi dogodki v anamnezi ali obstoječimi faktorji tveganja za trombembolične dogodke
the need to carry the patient safety card and to tell any healthcare practitioner that he/she is receiving treatment with eculizumab
potrebo po nošenju opozorilne kartice za bolnika in opozarjanju katerikoli zdravstvenih delavcev, s katerimi pridejo v stik, da prejemajo zdravljenje z ekulizumabom;
The need to check that the patient knows how to correctly use the bronchodilator.
treba je preveriti, ali bolnik zna pravilno uporabljati bronhodilatator.
the need to consider that co-administration of voriconazole and REYATAZ without ritonavir may affect atazanavir concentrations co-administration of fluticasone and REYATAZ without ritonavir may increase fluticasone concentrations relative to fluticasone given alone if an oral contraceptive is administered with REYATAZ without ritonavir, it is recommended that the oral contraceptive contain no more than 30 µg of ethinyloestradiol no dose adjustment of lamotrigine is required
upoštevati je treba pri sočasni uporabi vorikonazola in zdravila REYATAZ brez ritonavirja se lahko pojavi vpliv na koncentracije atazanavirja pri sočasni uporabi flutikazona in zdravila REYATAZ brez ritonavirja se lahko povečajo koncentracije flutikazona v primerjavi z uporabo flutikazona samega če bolnica uporablja peroralni kontraceptiv skupaj z zdravilom REYATAZ brez ritonavirja, je priporočljivo, da peroralni kontraceptiv ne vsebuje več kot 30 µg etinilestradiola odmerka lamotrigina ni treba prilagajati
The need to consider thromboprophylaxis after careful assessment of a patient’s risk factors
Potreba po razmisleku o tromboprofilaksi po natančni oceni bolnikovih dejavnikov tveganja
The need to contact the treating physician if they experience the following events:
potrebo po posvetu z zdravnikom v primeru naslednjih dogodkov:
The need to contact their doctor immediately upon suspicion of pregnancy
če sumi, da je noseča, mora o tem takoj obvestiti svojega zdravnika
The need to counsel patients about risks related to the administration of XALKORI and inform them of what symptoms and signs to be aware of and the actions to take.
Bolnikom je treba svetovati glede tveganj povezanih z dajanjem zdravila XALKORI in jih seznaniti s simptomi in znaki, na katere morajo biti pozorni, ter ustreznimi ukrepi.
The need to counsel patients about the risk of prolonged QTc and PRES and inform them of what symptoms and signs to be aware of and the actions to take
Potreba po svetovanju bolnikom glede tveganj za podaljšanje intervala QTc in PRES ter seznanitev bolnikov o simptomih in znakih na katere morajo biti pozorni ter kako je treba ukrepati.
The need to counsel patients on important risks associated with Eurartesim therapy and appropriate precautions when using the medicine.
O potrebi po svetovanju bolnikom o pomembnih tveganjih povezanih z zdravljenjem z zdravilom Eurartesim in o primernih varnostnih ukrepih med uporabo zdravila.
The need to counsel patients on important risks associated with leflunomide therapy and appropriate precautions when using the medicine.
O potrebi po svetovanju bolnikom o pomembnih tveganjih povezanih z zdravljenjem z leflunomidom in o primernih varnostnih ukrepih med uporabo zdravila.
The need to counsel patients on important risks associated with Vibativ therapy and appropriate precautions when using the medicine.
Bolnike je treba poučiti o pomembnih tveganjih, ki so povezana z zdravljenjem z zdravilom Vibativ, ter o ustreznih varnostnih ukrepih ob uporabi zdravila.
The need to ensure that women of child bearing age are using effective contraception and that patients should inform their doctors of any possibility of pregnancy before a new prescription is issued
da morajo ženske v rodni dobi uporabljati učinkovito kontracepcijo in da morajo bolnice svoje zdravnike obvestiti o možnosti zanositve preden jim zdravnik izda nov recept;